NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient

Article ID	Journal	Published Year	Pages	File Type
6119542	Journal of Clinical Virology	2016	15 Pages	PDF

Abstract

Herein we report a previously undescribed case of treatment-emergent non-structural protein 5A (NS5A) resistance mutations, Q30H and Y93C, leading to a failure of 24-week course of sofosbuvir/ledipasvirÂ +Â ribavirin therapy for the treatment of hepatitis C virus (HCV) genotype 1a in interferon-experienced, human immunodeficiency virus type 1 (HIV-1) co-infected patient with cirrhosis.

Keywords

INR end-of-treatment response ledipasvir LDV SOF Sofosbuvir non-structural protein 5B non-structural protein 5A NS5A NS3 NS5B RBV CART DDI DAA SVR PPI RT-PCR ALT AST Aspartate aminotransferase Alanine aminotransferase ribonucleic acid RNA Direct-acting antiviral interferon IFN Reverse transcriptase drug–drug interaction direct-acting antivirals combination antiretroviral therapy Ram Ribavirin Model for End-Stage Liver Disease Resistance Proton pump inhibitor Protease inhibitor International Normalized Ratio HCV Hepatitis C virus reverse transcription polymerase chain reaction HIV-1 HIV Human immunodeficiency virus type 1 non-structural protein 3 Genotype MELD